Lead sponsor
University Health Network, Toronto
11 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
11
Trials led
5
Active
665
Total enrollment
14
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
6
Phase 2/3
1
Phase 3
1
Phase 4
1
Not applicable
2
Trials by status
Not yet recruiting
2
By invitation
1
Recruiting
1
Active, not recruiting
1
Completed
3
Withdrawn
1
Unknown
2
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive DisorderBMI ≥25Ph 2Completed72
Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in HumansBMI 20-25not applicableCompleted15